Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT02555982
PHASE3

Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor

Sponsor: University Hospital, Clermont-Ferrand

View on ClinicalTrials.gov

Summary

Essential head tremor (HT) does not usually respond to drug treatment such as propranolol or primidone or to surgical treatment such as deep brain stimulation of the thalamic ventralis intermedius nucleus. Botulinum toxin (Btx) is widely used and efficient in the treatment of blepharospasm and cervical dystonia. Btx prevents the release of acetylcholine in synapses, leading to a reduction of pathological muscle movement. Very little information is available on its efficacy on HT. Two published reports suggested that local Btx A injections could be an effective and safe approach for treating HT. Given the scarcity of published data (small samples, open studies, different doses of Btx used, heterogeneous populations, several muscles injected, etc.), the aim of this study is to demonstrate the efficacy of Btx injections in essential HT by a multi-center, randomized, double-blind, parallel-group, placebo-controlled study. Principal objective: To evaluate the efficacy of botulinum toxin injections in the treatment of head tremor. Secondary objectives: * \- To evaluate the tolerance of botulinum toxin injections in the treatment of head tremor. * \- To evaluate the impact of botulinum toxin injections on the patients' quality of life and embarrassment. * To evaluate the changes of tremor characteristics induced by a Btx treatment using a 3D accelerometer wireless portable system (Xsens MTw wireless motion tracker system) (tremor frequency, tremor displacement, mean peak amplitude, distance traveled) and a new video system device to analyze head tremor characteristics

Official title: Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor by a Multi-center, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

120

Start Date

2016-06-27

Completion Date

2022-09-01

Last Updated

2026-04-21

Healthy Volunteers

No

Interventions

DRUG

BOTOX ® 200 Unités

Patients eligible for inclusion will be randomized to one of the two groups: * Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis). * Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).

DRUG

Placebo

Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).

Locations (17)

Centre Hospitalier Pays D'Aix

Aix-en-Provence, France

CHU d'Amiens

Amiens, France

Hôpital Jean Minjoz

Besançon, France

Hôpital Haut-Levêque

Bordeaux, France

CHU de Clermont-Ferrand

Clermont-Ferrand, France

Hôpital R Salendro

Lille, France

Hôpital neurologique

Lyon, France

Hôpital de la Timone

Marseille, France

CH Narbonne

Narbonne, France

Hôpital Caremeau

Nîmes, France

AP-HP

Paris, France

Fondation Rothschild

Paris, France

Hopital Lariboisière

Paris, France

Hôptal Avicenne de Bobigny

Paris, France

CHU de Poitiers

Poitiers, France

Hôpital de Hautepierre

Strasbourg, France

CHU de Toulouse

Toulouse, France